Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination

Molecular Pharmaceutics

Volumn 9, Issue 5, 2012, Pages 1361-1373

  Lee, Tien Yi ^a   Park, Yoon Shin ^a   Garcia, George A ^a   Sunahara, Roger K ^b   Woods, James H ^b   Yang, Victor C ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

cell penetrating peptides (CPP); cocaine esterase (CocE); low molecular weight protamine (LMWP); Tat

Indexed keywords

CARBOXYLESTERASE; CELL PENETRATING PEPTIDE; HYBRID PROTEIN; LOW MOLECULAR WEIGHT PROTAMINE; MUTANT PROTEIN; PROTEIN VARIANT; RECOMBINANT PROTEIN; TAT PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL ENCAPSULATION; CELL PERMEABILIZATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; CONJUGATION; ENZYME STABILITY; FEMALE; GENETIC RECOMBINATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOGENICITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN PURIFICATION; SYNTHESIS;

CARBOXYLIC ESTER HYDROLASES; CELL-PENETRATING PEPTIDES; CHROMATOGRAPHY, AFFINITY; HELA CELLS; HUMANS; PEPTIDE FRAGMENTS; PROTAMINES; RECOMBINATION, GENETIC;

EID: 84860707029     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200623w     Document Type: Article

References (50)

1. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2011; 2011; pp 85-126.
2. Boghdadi, M. S.; Henning, R. J. Cocaine: pathophysiology and clinical toxicology Heart Lung 1997, 26 (6) 466-83
3. Bresler, M. M.; Rosser, S. J.; Basran, A.; Bruce, N. C. Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1 Appl. Environ. Microbiol. 2000, 66 (3) 904-8
4. Turner, J. M.; Larsen, N. A.; Basran, A.; Barbas, C. F., 3rd; Bruce, N. C.; Wilson, I. A.; Lerner, R. A. Biochemical characterization and structural analysis of a highly proficient cocaine esterase Biochemistry 2002, 41 (41) 12297-307
5. Cooper, Z. D.; Narasimhan, D.; Sunahara, R. K.; Mierzejewski, P.; Jutkiewicz, E. M.; Larsen, N. A.; Wilson, I. A.; Landry, D. W.; Woods, J. H. Rapid and Robust Protection against Cocaine-Induced Lethality in Rats by the Bacterial Cocaine Esterase Mol. Pharmacol. 2006, 70 (6) 1885-91
6. Gao, D.; Narasimhan, D. L.; Macdonald, J.; Brim, R.; Ko, M. C.; Landry, D. W.; Woods, J. H.; Sunahara, R. K.; Zhan, C. G. Thermostable Variants of Cocaine Esterase for Long-Time Protection against Cocaine Toxicity Mol. Pharmacol. 2008, 75 (2) 318-23
7. Brim, R. L.; Nance, M. R.; Youngstrom, D. W.; Narasimhan, D.; Zhan, C. G.; Tesmer, J. J. G.; Sunahara, R. K.; Woods, J. H. A Thermally Stable Form of Bacterial Cocaine Esterase: A Potential Therapeutic Agent for Treatment of Cocaine Abuse Mol. Pharmacol. 2010, 77 (4) 593-600
8. Park, J.-B.; Kwon, Y. M.; Lee, T.-Y.; Brim, R.; Ko, M.-C.; Sunahara, R. K.; Woods, J. H.; Yang, V. C. PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity J. Controlled Release 2010, 142 (2) 174-9
9. Beutler, E.; Dale, G. L.; Guinto, D. E.; Kuhl, W. Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation Proc. Natl. Acad. Sci. U.S.A. 1977, 74 (10) 4620-3
10. Muthuvel, A.; Rajamani, R.; Manikandan, S.; Sheeladevi, R. Detoxification of formate by formate dehydrogenase-loaded erythrocytes and carbicarb in folate-deficient methanol-intoxicated rats Clin. Chim. Acta 2006, 367 (1-2) 162-9
11. Kwon, Y. M.; Chung, H. S.; Moon, C.; Yockman, J.; Park, Y. J.; Gitlin, S. D.; David, A. E.; Yang, V. C. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL) J. Controlled Release 2009, 139 (3) 182-9
12. Gutierrez Millan, C.; Marinero, M. L.; Castaneda, A. Z.; Lanao, J. M. Drug, enzyme and peptide delivery using erythrocytes as carriers J. Controlled Release 2004, 95 (1) 27-49
13. Othman, A. A.; Syed, S. A.; Newman, A. H.; Eddington, N. D. Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse J. Pharmacol. Exp. Ther. 2007, 320 (1) 344-53
14. Javaid, J. I.; Dekirmenjian, H.; Davis, J. M.; Schuster, C. R. Determination of cocaine in human urine, plasma and red blood cells by gas-liquid chromatography J. Chromatogr. 1978, 152 (1) 105-13
15. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46 (1-3) 3-26
16. Collins, G. T.; Brim, R. L.; Narasimhan, D.; Ko, M. C.; Sunahara, R. K.; Zhan, C. G.; Woods, J. H. Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats J. Pharmacol. Exp. Ther. 2009, 331 (2) 445-55
17. Fawell, S.; Seery, J.; Daikh, Y.; Moore, C.; Chen, L. L.; Pepinsky, B.; Barsoum, J. Tat-mediated delivery of heterologous proteins into cells Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (2) 664-8
18. Hallbrink, M.; Floren, A.; Elmquist, A.; Pooga, M.; Bartfai, T.; Langel, U. Cargo delivery kinetics of cell-penetrating peptides Biochim. Biophys. Acta 2001, 1515 (2) 101-9
19. Heitz, F.; Morris, M. C.; Divita, G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics Br. J. Pharmacol. 2009, 157 (2) 195-206
20. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus J. Biol. Chem. 1997, 272 (25) 16010-7
21. Chen, L.; Harrison, S. D. Cell-penetrating peptides in drug development: enabling intracellular targets Biochem. Soc. Trans. 2007, 35 (Part 4) 821-5
22. Schwarze, S. R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. F. In vivo protein transduction: delivery of a biologically active protein into the mouse Science 1999, 285 (5433) 1569-72
23. Leifert, J. A.; Harkins, S.; Whitton, J. L. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity Gene Ther. 2002, 9 (21) 1422-8
24. Byun, Y.; Singh, V. K.; Yang, V. C. Low molecular weight protamine: a potential nontoxic heparin antagonist Thromb. Res. 1999, 94 (1) 53-61
25. Park, Y. J.; Liang, J. F.; Ko, K. S.; Kim, S. W.; Yang, V. C. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study J. Gene Med. 2003, 5 (8) 700-11
26. Park, Y. S.; Huang, Y.; Park, Y. J.; David, A. E.; White, L.; He, H.; Chung, H. S.; Yang, V. C. Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1α-oligonucleotide J. Controlled Release 2010, 144 (1) 82-90
27. Park, Y. J.; Chang, L. C.; Liang, J. F.; Moon, C.; Chung, C. P.; Yang, V. C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study FASEB J. 2005, 19 (11) 1555-7
28. Kwon, Y. M.; Li, Y. T.; Liang, J. F.; Park, Y. J.; Chang, L. C.; Yang, V. C. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation J. Controlled Release 2008, 130 (3) 252-8
29. Chang, L. C.; Lee, H. F.; Yang, Z.; Yang, V. C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization AAPS PharmSci 2001, 3 (3) E17
30. Lee, L. M.; Chang, L. C.; Wrobleski, S.; Wakefield, T. W.; Yang, V. C. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model AAPS PharmSci 2001, 3 (3) E19
31. Liang, J. F.; Zhen, L.; Chang, L. C.; Yang, V. C. A less toxic heparin antagonist - low molecular weight protamine Biochemistry (Moscow) 2003, 68 (1) 116-20
32. Tsui, B.; Singh, V. K.; Liang, J. F.; Yang, V. C. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue Thromb. Res. 2001, 101 (5) 417-20
33. Richard, J. P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M. J.; Chernomordik, L. V.; Lebleu, B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake J. Biol. Chem. 2003, 278 (1) 585-90
34. Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A Comprehensive Model for the Cellular Uptake of Cationic Cell-penetrating Peptides Traffic 2007, 8 (7) 848-66
35. Narasimhan, D.; Nance, M. R.; Gao, D.; Ko, M. C.; Macdonald, J.; Tamburi, P.; Yoon, D.; Landry, D. M.; Woods, J. H.; Zhan, C. G.; Tesmer, J. J. G.; Sunahara, R. K. Structural analysis of thermostabilizing mutations of cocaine esterase Protein Eng., Des. Sel. 2010, 23 (7) 537-547
36. Carlsson, J.; Drevin, H.; Axen, R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent Biochem. J. 1978, 173 (3) 723-37
37. Sawano, A.; Miyawaki, A. Directed evolution of green fluorescent protein by a new versatile PCR strategy for site-directed and semi-random mutagenesis Nucleic Acids Res. 2000, 28 (16) E78
38. Larsen, N. A.; Turner, J. M.; Stevens, J.; Rosser, S. J.; Basran, A.; Lerner, R. A.; Bruce, N. C.; Wilson, I. A. Crystal structure of a bacterial cocaine esterase Nat. Struct. Biol. 2002, 9 (1) 17-21
39. Gatley, S. J. Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase Biochem. Pharmacol. 1991, 41 (8) 1249-54
40. Rothe, R.; Liguori, L.; Villegas-Mendez, A.; Marques, B.; Grunwald, D.; Drouet, E.; Lenormand, J. L. Characterization of the Cell-penetrating Properties of the Epstein-Barr Virus ZEBRA trans-Activator J. Biol. Chem. 2010, 285 (26) 20224-33
41. Ziegler, A.; Seelig, J. High affinity of the cell-penetrating peptide HIV-1 Tat-PTD for DNA Biochemistry 2007, 46 (27) 8138-45
42. Kharidia, R.; Friedman, K. A.; Liang, J. F. Improved gene expression using low molecular weight peptides produced from protamine sulfate Biochemistry (Moscow) 2008, 73 (10) 1162-8
43. Kane, J. F. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli Curr. Opin. Biotechnol. 1995, 6 (5) 494-500
44. Goldman, E.; Rosenberg, A. H.; Zubay, G.; Studier, F. W. Consecutive low-usage leucine codons block translation only when near the 5′ end of a message in Escherichia coli J. Mol. Biol. 1995, 245 (5) 467-73
45. Becker-Hapak, M.; Dowdy, S. Protein transduction: generation of full-length transducible proteins using the TAT system. In Current Protocols in Cell Biology; Wiley: New York, 2003; Vol. 18, pp 20.2.01-25.
46. Lo, S. L.; Wang, S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection Biomaterials 2008, 29 (15) 2408-14
47. Wadia, J. S.; Stan, R. V.; Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis Nat. Med. 2004, 10 (3) 310-5
48. Guyton, A. G.; Hall, J. E., Red blood cells, anemia and polycytemica. In Textbook of Medical Physiology; W. B. Saunders: Philadelphia, 1996; pp 425-33.
49. Illum, L. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 2004, 56 (1) 3-17
50. Carrera, M. R.; Kaufmann, G. F.; Mee, J. M.; Meijler, M. M.; Koob, G. F.; Janda, K. D. Treating cocaine addiction with viruses Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (28) 10416-21